Is Pacira BioSciences, Inc. (PCRX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 44.2% / 30% | 25.2% / 30% | 13.1% / 30% | 3.13% / 5% | ✗ NOT HALAL |
| DJIM | 44.2% / 33% | 25.2% / 33% | 13.1% / 33% | 3.13% / 5% | ✗ NOT HALAL |
| MSCI | 33.1% / 33% | 18.8% / 33% | 9.8% / 33% | 3.13% / 5% | ✓ HALAL |
| S&P | 44.2% / 33% | 25.2% / 33% | 13.1% / 33% | 3.13% / 5% | ✗ NOT HALAL |
| FTSE | 33.1% / 33% | 18.8% / 33% | 9.8% / 50% | 3.13% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 63.2% | |
| Operating Margin | -1.2% | |
| Net Margin | 1.0% | |
| Return on Equity (ROE) | 1.0% | |
| Return on Assets (ROA) | 1.5% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $152M |
| Free Cash Flow | $137M |
| Total Debt | $418M |
| Debt-to-Equity | 60.3 |
| Current Ratio | 4.5 |
| Total Assets | $1.3B |
Price & Trading
| Last Close | $23.31 |
| 50-Day MA | $21.85 |
| 200-Day MA | $23.59 |
| Avg Volume | 910K |
| Beta | 0.2 |
|
52-Week Range
$18.80
| |
About Pacira BioSciences, Inc. (PCRX)
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Pacira BioSciences, Inc. (PCRX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Pacira BioSciences, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Pacira BioSciences, Inc.'s debt ratio?
Pacira BioSciences, Inc.'s debt ratio is 44.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 33.1%.
What are Pacira BioSciences, Inc.'s key financial metrics?
Pacira BioSciences, Inc. has a market capitalization of $984M, trailing P/E ratio of 143.0, and revenue of $726M. The company maintains a gross margin of 63.2% and a net margin of 1.0%. Return on equity stands at 1.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.